Rani Shares Positive Oral Ustekinumab Data After Last Year’s Challenges

RT-111 Oral Ustekinumab Biosimilar Passes Phase I Trial After Company Prioritization

 
• By Adam Zamecnik

Rani Therapeutics announced positive topline results from a Phase I trial of its oral Stelara biosimilar, moving it further in a crowded market with fierce competition.

Woman Taking Pill With Glass Of Water
The Oral Ustekinumab Biosimilar Passed Its Phase I Study • Source: Shutterstock

More from Biosimilars

More from Products